Subsequent approvals of PD-1 and PD-L1 inhibitors, such as nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab, have significantly improved outcomes across various cancers [19]. This evidence concerns the gene CD274 and cancer.